- |||||||||| GTAEXS-617 / Exscientia, GT Apeiron Therap
Defining activity and patient selection of a novel CDK7 inhibitor, GTAEXS-617, through AI-supported primary cancer tissue profiling (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_263;
Ex vivo cancer cell sensitivity differences in various ovarian cancer grades, as identified by correlation of phenotypic response to differential single cell transcriptomics after '617 perturbation, indicates a potential stratification point that could be used for patient enrichment in clinical trials. Further, '617 displayed less cytotoxic effects on the immune compartment than other CDK7 and CDK4/6 inhibitors.
- |||||||||| GTAEXS-617 / Exscientia, GT Apeiron Therap
AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7 (Section 22) - Mar 9, 2022 - Abstract #AACR2022AACR_6019;
In summary, Excientia’s AI platform enabled rapid and highly efficient discovery of ‘617, an orally bioavailable CDK7 inhibitor, demonstrating potent anti-tumour activity in vivo and preferential activity against primary human tumour cells vs non-transformed immune cells. These data support the advancement of ‘617 towards clinical development.
|
